GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Inclusion Criteria: * Adult subjects 18 and older with chronic HCV infection * Liver biopsy results (performed no more than 3 years prior to Screening) indicating the absence of cirrhosis * Monoinfection with HCV genotype 1a or 1b * Interferon ineligible or intolerant * Body mass index (BMI) between 18 and 40 kg/m2 * Use of highly effective contraception methods if female of childbearing potential or sexually active male * Screening laboratory values within defined thresholds * Has not been exposed to any investigational drug or device within 30 days of the Screening visit * Able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments Exclusion Criteria: * Prior treatment of HCV with any direct-acting antiviral (whether approved or experimental) * Decompensated liver disease or cirrhosis * Co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype * History of difficulty with blood collection and/or poor venous access * Pregnant or nursing female or male with pregnant female partner * Chronic liver disease of a non-HCV etiology * Suspicion of hepatocellular carcinoma * Clinically-relevant drug abuse